Novartis China Growth Slows Sharply In 2Q
This article was originally published in PharmAsia News
Executive Summary
China’s economic slowdown has hit Novartis hard, with the Swiss multinational’s second quarter growth in the country being slashed by around half. Despite the company emphasizing the challenges are short-term, the underlying reasons such as growing generic competition from domestic companies could be far-reaching.